Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (NCT03947385) — Canada Trial Details

Condition(s) studied

Metastatic Uveal MelanomaCutaneous MelanomaColorectal CancerOther Solid Tumors

Investigational drug(s) / intervention(s)

IDE196: IDE196 dosed orally, twice daily for each 28-day cycle

Binimetinib: Binimetinib dosed orally, twice daily for each 28-day cycle

Crizotinib: Crizotinib dosed orally, twice daily for each 28-day cycle

Study summary

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors.

Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.

Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.

Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study.

Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity.

As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

No

Inclusion Criteria: * Patient must be ≥18 years of age and able to provide written informed consent * Diagnosis of the following: o MUM: Uveal melanoma with histological or cytological confirmed metastatic disease. Metastatic disease may be treatment naïve or have progressed on or after most recent therapy. If the most recent therapy was an immune-oncology agent, PD must be confirmed. \- If a patient is treatment naïve and human leukocyte antigen (HLA)-A\*02:01 positive\*\*\*, documentation is required to provide rationale why treatment with tebentafusp is not the ideal firstline treatment approach or of the patient's intolerance to tebentafusp. \*\*\*To be enrolled in the HLA-A\*02:01 positive cohort, HLA status must be documented by test results from a CAP/CLIA-certified laboratory. * Measurable disease per RECIST v1.1 * Eastern Cooperative Oncology Group ≤1 and expected life expectancy of \> 3 months * Adequate organ function at screening * Adequate contraceptive measures for non-sterilized male and female patients of childbearing potential Crizotinib Combination Additional Inclusion Criteria: * Prior chemotherapy other therapies as applicable or major surgeries must have been completed at least 4 weeks prior to initiation of crizotinib * Patients with preexisting peripheral neuropathy can be included if it is Grade 1 or lower, prior to initiation of crizotinib Biopsy-eligible patients * Accessible lesion(s) that permit a total of at least two biopsies without unacceptable risk of a significant procedural complication. Exclusion Criteria: * Previous treatment with a PKC inhibitor * Known MSI-H/dMMR tumors who have not previously received immune checkpoint inhibitors * Known symptomatic brain metastases * Adverse events from prior anti-cancer therapy that have not resolved * Known acquired immunodeficiency syndrome (AIDS)-related illness, hepatitis B virus, or hepatitis C virus * Active infection requiring ongoing therapy * Recent surgery or radiotherapy * Prior gastrectomy or upper bowel removal or any other gastrointestinal disorder or defect * Females who are pregnant or breastfeeding * Impaired cardiac function * Treatment with prohibited medications that cannot be discontinued prior to study entry * For patients receiving IDE196 powder-in-capsule (PIC) formulation or crizotinib, allergy to mammalian meat products and gelatin Crizotinib Combination Additional Exclusion Criteria: * Prior therapy directly targeting ALK, MET, or ROS1 * Spinal cord compression * History of pneumonitis or interstitial lung disease * History of syncope * History of thromboembolic or cerebrovascular events ≤12 weeks prior to first dose of study treatment PK Substudy (optional) with Pravastatin Additional Exclusion Criteria: * Taken any dose of statin or inhibitor of organic anion transporting polypeptide within 7 days prior to enrollment in the study and cannot refrain from them through C2D1 * Taken drugs that interfere with the absorption, metabolism, or elimination of pravastatin * Any contraindication associated to the use of statins or hypersensitivity component of pravastatin * Active liver disease DDI Cocktail Substudy Additional Exclusion Criteria: * Treatment with bupropion, repaglinide, flurbiprofen, omeprazole, esomeprazole, midazolam, and dabigatran etexilate within 7 days prior to Cycle 1 Day -1. * Intake of vitamin supplements containing Vitamin B6 (pyridoxine), grapefruit/grapefruit juice, or Seville orange juice within 7 days prior to Cycle 1 Day -1. * Intake of any strong or moderate inhibitor of CYP2B6, CYP2CI, CYP2C9, CYP2C10 and OAT3 is prohibited within 7 days or within 5 half-lives, whichever is longer, of Cycle 1 Day -1. * Moderate and strong inhibitors of CYP2A4/5 or P-gp are prohibited within 7 days, or within 5 half-lives, whichever is longer, of Cycle 1 Day -1. * Intake of strong or moderate inducers of CYP3A4/5, CYP2B6, CYP2C9, CYP2C19, or OAT3 is prohibited during 15 days, or 5 half-lives, whichever is longer, prior to Cycle 1 Day -1.

Primary outcome measure(s)

Dose-limiting Toxicity (DLT) — 28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Determine DLT of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Incidence of Adverse Events — Approx. 8 months
Safety and tolerability of IDE196 either as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Maximum Tolerated Dose (MTD) — 28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Determine MTD of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Recommended Phase 2 Dose (RP2D) as monotherapy, in combination with Binimetinib, or in combination with Crizotinib — Approx. 6 months
Determine RP2D of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Plasma Concentrations of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib — Approx. 6 months
Pharmacokinetics of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
Plasma Concentrations of Crizotinib administered in combination with IDE196 — Approx. 6 months
Pharmacokinetics of Crizotinib in combination with IDE196
Plasma Concentrations of Binimetinib administered in combination with IDE196 — Approx. 6 months
Pharmacokinetics of Binimetinib in combination with IDE196
Overall Response Rate (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment — Approx. 8 months
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) criteria
Duration of Response (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment — Approx. 8 months
RECIST v1.1

Trial sites (15)

Facility	City	Region	Status
UCLA Medical Center	Los Angeles	California	Recruiting
San Francisco Oncology Associates	San Francisco	California	Active Not Recruiting
SCRI - Denver	Denver	Colorado	Recruiting
University of Iowa	Iowa City	Iowa	Active Not Recruiting
Cancer Hematology Centers Western Michigan	Grand Rapids	Michigan	Active Not Recruiting
Columbia University Medical Center - Herbert Irving Pavilion	New York	New York	Active Not Recruiting
Duke University Medical Center	Durham	North Carolina	Recruiting
University of Cincinnati Cancer Center	Cincinnati	Ohio	Recruiting
The Cleveland Clinic Foundation	Cleveland	Ohio	Active Not Recruiting
Sidney Kimmel Cancer Center at Thomas Jefferson University	Philadelphia	Pennsylvania	Recruiting
The Sarah Cannon Research Institute/Tennessee Oncology	Nashville	Tennessee	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	Recruiting
Westmead Hospital	Sydney	New South Wales	Active Not Recruiting
Queensland	Woolloongabba	Australia	Active Not Recruiting
Princess Margaret Cancer Centre	Toronto	Ontario	Active Not Recruiting

More IDEAYA Biosciences trials in Canada

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma Recruiting

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Active, not recruiting

Neoadjuvant Darovasertib in Primary Uveal Melanoma Recruiting

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Active, not recruiting

Other trials for the same condition

Ontario-wide Cancer TArgeted Nucleic Acid Evaluation Recruiting

Integrated Molecular Profiling in Advanced Cancers Trial Active, not recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors Recruiting

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) Recruiting

Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps Recruiting